Abstract
B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Volume: 16 Issue: 4
Author(s): Bin Yuan, Hong Zhao, Xiaofeng Xue, Jin Zhou, Xu Wang, Ye Han, Lifeng Zhang, Xiaobo Guo and Qiaoming Zhi
Affiliation:
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Abstract: B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Export Options
About this article
Cite this article as:
Yuan Bin, Zhao Hong, Xue Xiaofeng, Zhou Jin, Wang Xu, Han Ye, Zhang Lifeng, Guo Xiaobo and Zhi Qiaoming, Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150507120801
DOI https://dx.doi.org/10.2174/1871520615666150507120801 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy
Current Molecular Pharmacology Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Malignant Pleural Effusion Evaluation and Management
Current Respiratory Medicine Reviews Biosynthesis of Copper Oxide Nanoparticles Using Lactobacillus casei Subsp. Casei and its Anticancer and Antibacterial Activities
Current Nanoscience Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Multiligand Endocytosis and Congenital Defects: Roles of Cubilin, Megalin and Amnionless
Current Pharmaceutical Design Detecting Personalized Determinants During Drug Treatment from Omics Big Data
Current Pharmaceutical Design Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Coping With Oxidative Stress. The Yeast Model
Current Drug Targets Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry The Synergistic Cytotoxic and Apoptotic Effect of Resveratrol and Naringenin on Y79 Retinoblastoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Reductions in Medications with Substantial Weight Loss with Behavioral Intervention
Current Clinical Pharmacology Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism